TCVS

01/01/2019 - "The results of this trial may provide important evidence to support the introduction of TCVs in countries with a high burden of typhoid. "
12/01/2017 - "Discussion topics included (1) the latest evidence and data gaps in typhoid epidemiology; (2) WHO and Gavi methods and data requirements; (3) data on TCV efficacy; (4) cost effectiveness analysis for TCVs from mathematical models; (5) TCV delivery and effectiveness study design. "
05/01/2023 - "It is vital to empower decision-makers in typhoid-endemic countries to introduce TCVs and for leaders to embrace this critical tool to prevent typhoid fever, slow the spread of drug-resistant S. "
05/01/2023 - "Broad and equitable distribution of TCVs is essential to combat the spread and potentially devastating consequences of typhoid fever. "
10/01/2022 - "We review efficacy and effectiveness data for TCVs, which have been shown to have high-level efficacy (≥80%) against typhoid fever in diverse field settings. "

01/01/2023 - "Furthermore, there is an urgent need for personalized TCVs because only a limited number of tumor antigens are shared among cancer patients. "
01/01/2022 - "Therapeutic cancer vaccines (TCVs) should induce robust tumor-specific T cell responses. "
01/01/2021 - "Telomerase stands as an attractive target for TCVs due to its almost universal presence in cancer and its essential function promoting tumor growth. "
01/01/2023 - "The therapeutic efficacy of whole tumor cell vaccines (TCVs) is modest, which has delayed their translation into personalized immunotherapies in the clinic. "
01/01/2021 - "Therapeutic cancer vaccines (TCVs) are attractive systemic immunotherapies that activate and expand antigen-specific CD8+ and CD4+ T cells to enhance anti-tumor immunity. "

04/01/2005 - "Previously, an ecological study showing a significant association between TCVs and neurodevelopmental disorders (NDs) in the US was published in this journal. "
11/01/2003 - "Relative risks for neurodevelopmental disorders were calculated per increase of 12.5 micro g of estimated cumulative mercury exposure from TCVs in the first, third, and seventh months of life. "
08/15/2008 - "The study evaluated possible associations between neurodevelopmental disorders (NDs) and exposure to mercury (Hg) from Thimerosal-containing vaccines (TCVs) by examining the automated Vaccine Safety Datalink (VSD). "

01/01/2011 - "Our study revealed no evidence of an association between TCVs and autism."
01/01/2011 - "After adjusting to potential confounders, odds ratios of the risk of autism developing for infants vaccinated with TCVs were 1.52 (95% CI: 0.29-11.11) for doses 12.5-87.5 microg, 2.78 (95% CI: 0.29-11.11) for 100-137.5 microg and 1.97 (95% CI: 0.37-18.95) for these exposed > or = 150 microg. "
01/01/2011 - "No significant association was found between TCVs exposure and autism. "
01/01/2011 - "Conditional logistic regression was used to assess the risk of autism due to TCVs exposure. "
01/01/2011 - "The objective of this analysis was to determine an association of TCVs exposure with the risk of autism. "

02/15/2003 - "A descriptive study involving the evaluation of the medical records of patients that met the following criteria: over 18 years of age with a diagnosis of TCVS confirmed by CAT scan or cranial MRI, the absence of a history of intracranial surgery in the previous six months and absence of a history of intracranial infection. "
01/01/2019 - "A deterministic transmission dynamic model was developed to simulate the impact of TCVs on the number and proportion of antimicrobial-resistant typhoid infections and chronic carriers. "
01/01/2019 - "The introduction of typhoid conjugate vaccines (TCVs) in these settings may relieve this selective pressure, thereby reducing resistant infections and improving health outcomes. "